AJIC: American Journal of Infection Control
Volume 37, Issue 9 , Pages 753-758 , November 2009

Previous ciprofloxacin exposure is associated with resistance to β-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates

  • Miguel López-Dupla, MD

      Affiliations

    • Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
    • Corresponding Author InformationAddress correspondence to Miguel Lopez-Dupla, MD, Servei de Medicina Interna, Hospital Universitari de Tarragona Joan XXIII, C/Dr. Mallafré Guasch, 4, 43007 Tarragona, Spain.
    • ,
  • José-Antonio Martínez, MD

      Affiliations

    • Hospital Clínic, IDIBAPS, Barcelona, Spain
    • ,
  • Francesc Vidal, MD

      Affiliations

    • Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
    • ,
  • Manuel Almela, MD

      Affiliations

    • Hospital Clínic, IDIBAPS, Barcelona, Spain
    • ,
  • Alex Soriano, MD

      Affiliations

    • Hospital Clínic, IDIBAPS, Barcelona, Spain
    • ,
  • Francesco Marco, MD

      Affiliations

    • Hospital Clínic, IDIBAPS, Barcelona, Spain
    • ,
  • Josefina López, MD

      Affiliations

    • Hospital Clínic, IDIBAPS, Barcelona, Spain
    • ,
  • Montserrat Olona, MD

      Affiliations

    • Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain
    • ,
  • Josep Mensa, MD

      Affiliations

    • Hospital Clínic, IDIBAPS, Barcelona, Spain

References 

  1. D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol. 2004;25:842–846
  2. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003;36(Suppl 1):S11–S23
  3. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–485
  4. Pop-Vicas AE, D'Agata EM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis. 2005;40:1792–1798
  5. Carsenti-Etesse H, Cavallo JD, Roger PM, Ziha-Zarifi I, Plesiat P, Garrabe E, et al. Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa. Clin Microbiol Infect. 2001;7:144–151
  6. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother. 2005;55:535–541
  7. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist. 2005;11:68–74
  8. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect. 2004;57:209–216
  9. Ortega B, Groeneveld ABJ, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol. 2004;25:825–831
  10. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002;34:634–640
  11. Livermore DM. Of pseudomonas, porins, pumps, and carbapems. J Antimicrob Chemother. 2001;47:247–250
  12. Ziha-Zarifi I, Llanes C, Köhler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother. 1999;43:287–291
  13. Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Antimicrob Agents Chemother. 2005;49:2543–2545
  14. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plésiat P, Bingen E. In vivo selection of target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother. 2001;48:553–555
  15. Niederman MS. Impact of antibiotic resistance on clinical outcomes ant the cost of care. Crit Care Med. 2001;29(Suppl 4):N114–N120
  16. Anonymous . The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol. 2002;23:106–108
  17. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother. 2002;46:854–858
  18. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis. 2002;34:340–345
  19. Fortaleza CM, Freire MP, Filho D de C, de Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol. 2006;27:901–906
  20. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis. 2002;34:1047–1054
  21. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 1997;25:1094–1098
  22. Lopez-Dupla M, Martinez JA, Vidal F, Almela M, López J, Marco F, et al. Clinical characterization of breakthrough bacteremia: a survey of 392 episodes. J Intern Med. 2005;258:172–180
  23. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med. 1996;156:2121–2126
  24. Vidal F, Mensa J, Martinez JA, Almela M, Marco F, Gatell JM, et al. Pseudomonas aeruginosa bacteremia in patients infected by the human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis. 1999;18:473–477
  25. Vidal F, Mensa J, Almela M, Olona M, Martinez JA, Marco F, et al. Bacteraemia in adults due to glucose non-fermentative gram-negative bacilli other than P aeruginosa. Q J Med. 2003;96:227–234
  26. National Committee for Clinical Laboratory Standards. Methods for the dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 1990. 2nd ed. Approved standard M7-A2. Villanova, PA: National Committee for Clinical and Laboratory Standards.
  27. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004;38:670–677
  28. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med. 1962;110:847–855
  29. CDC. National Nosocomial Infections Study. Site definitions manual. Atlanta, GA: Centers for Disease Control and Prevention; 1972;
  30. Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2920–2925
  31. Aubert G, Carricajo A, Vautrin AC, Guyomarc'h S, Fonsale N, Page D, et al. Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect. 2005;59:83–89
  32. Neuhauser MM, Weinstein RA, Rydman R, Danizger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885–888
  33. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006;27:893–900
  34. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382
  35. Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Clin Infect Dis. 2005;41:441–449
  36. Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistance in the intensive care unit. Crit Care Med. 2005;33:283–289
  37. Schwaber MJ, Cosgrove SE, Gold HS, Kaye KS, Carmeli Y. Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens. Emerg Infect Dis. 2004;10:94–99
  38. Sobel ML, Neshat S, Poole K. Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol. 2005;187:1246–1253
  39. Lee SC, Fung CP, Liu PY, Wang TC, See LC, Lee N, et al. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome. Infect Control Hosp Epidemiol. 1999;20:205–207
  40. El Amari EB, Chamot E, Auckenthaler R, Pechère JC, Delden V. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001;33:1859–1864
  41. McGowan JE. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control. 2006;34(Suppl 1):S29–S37
  42. Could CV, Rothenberg R, Steinberg JP. Antibiotic resistance in long-term acute care hospitals: the perfect storm. Infect Control Hosp Epidemiol. 2006;27:920–925
  43. Lautenbach E, Polk RE. Resistant gram-negative bacilli: a neglected healthcare crisis?. Am J Health Syst Pharm. 2007;64(Suppl 14):S3–S21

 Supported in part by a grant from the Fundación Máximo Soriano Jiménez.

 Conflicts of interest: None to report.

PII: S0196-6553(09)00428-3

doi: 10.1016/j.ajic.2009.02.003

AJIC: American Journal of Infection Control
Volume 37, Issue 9 , Pages 753-758 , November 2009

Article Tools